Genzyme launches defence against Sanofi
Health / Medicine Related News
Genzyme said the $18.5bn offer ignored a recovery at its manufacturing plants and a strong drug pipeline that would together drive substantial earnings growth by 2013
Source: FT.com - Pharmaceuticals